alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 87, Number 21 (Tuesday, February 1, 2022)]
[Notices]
[Page 5483]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01950]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP)--CE22-007: Reduce Health Disparities and Improve 
Traumatic Brain Injury (TBI) Related Outcomes Through the 
Implementation of CDC's Pediatric Mild TBI Guideline; Amended Notice of 
Meeting

    Notice is hereby given of a change in the meeting of the Disease, 
Disability, and Injury Prevention and Control Special Emphasis Panel 
(SEP)--CE22-007: Reduce Health Disparities and Improve Traumatic Brain 
Injury (TBI) Related Outcomes Through the Implementation of CDC's 
Pediatric Mild TBI Guideline; June 6-7, 2022, 8:30 p.m.-5:30 p.m., EDT, 
Videoconference.
    The Videoconference meeting was published in the Federal Register 
on January 14, 2022, Volume 87, Number 10, page 2438.
    The meeting is being amended to correct the dates of the special 
emphasis panel and should read as follows:
    Date: June 7-8, 2022.
    The meeting is closed to the public.
    For Further Information Contact: Mikel Walters, Ph.D., Scientific 
Review Official, National Center for Injury Prevention and Control, 
CDC, 4770 Buford Highway NE, Mailstop F-63, Atlanta, Georgia 30341, 
Telephone (404) 639-0913, <a href="/cdn-cgi/l/email-protection#602d37010c14051213200304034e070f16"><span class="__cf_email__" data-cfemail="b0fde7d1dcc4d5c2c3f0d3d4d39ed7dfc6">[email protected]</span></a>.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-01950 Filed 1-31-22; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in
Registration Statements on Form S-3, SEC File Nos. 333-140166, 333-141920, 333-147641, and 333-148300 and on Form S-8, SEC file Nos. 333-50325, 333-76038, 333-50343 and 333-134631 of our reports dated February 11, 2008, relating to the
financial statements of Odyssey Marine Exploration, Inc. and Subsidiaries, and managements report on the effectiveness of internal control over financial reporting appearing in this Annual Report on Form 10-K of Odyssey Marine Exploration,
Inc. and Subsidiaries for the year ended December 31, 2007.



|                                   
|-----------------------------------
|/s/ Ferlita, Walsh & Gonzalez, P.A.
|Ferlita, Walsh & Gonzalez, P.A.    
|3302 Azeele Street                 
|Tampa, Florida 33609               

March 13, 2008
<PAGE>   1
                                                                      EXHIBIT 23

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in Registration Statement No.
33-48560 on Form S-8, in Registration Statement No. 33-46993 on Form S-8 and in
Registration Statement No. 333-59759 on Form S-8 of Lechters, Inc. and
subsidiaries of our report dated March 24, 1999, appearing in this Annual Report
on Form 10-K of Lechters Inc. and subsidiaries for the year ended January 30,
1999.


DELOITTE & TOUCHE LLP

Parsippany, New Jersey
April 27, 1999
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 16-6220

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

v.

FLOYD JUNIOR POWELL, a/k/a Dick,

Defendant - Appellant.

Appeal from the United States District Court for the Western 

District of North Carolina, at Statesville. Richard L. 

Voorhees, District Judge. (5:99-cr-00012-V-6; 5:15-cv-00092-

RLV)

Submitted: June 16, 2016 Decided: June 22, 2016

Before NIEMEYER, KING, and DUNCAN, Circuit Judges.

Affirmed by unpublished per curiam opinion.

Floyd Junior Powell, Appellant Pro Se. Amy Elizabeth Ray, 

Assistant United States Attorney, Asheville, North Carolina, for 

Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Floyd Junior Powell appeals the district court’s order 

denying his post-judgment motion for recusal as moot. We have 

reviewed the record and find no reversible error. Accordingly, 

we affirm for the reasons stated by the district court. See

United States v. Powell, No. 5:15-cv-00092-RLV (W.D.N.C. Jan. 

19, 2016). We dispense with oral argument because the facts and 

legal contentions are adequately presented in the materials 

before this court and argument would not aid the decisional 

process.

AFFIRMED
Case: 1:18-cr-00109-TSB Doc #: 84 Filed: 02/14/19 Page: 1 of 1 PAGEID #: 524
1Pursuant to 5TH CIR. R. 47.5, the Court has determined that

this opinion should not be published and is not precedent except

under the limited circumstances set forth in 5TH CIR. R. 47.5.4.

UNITED STATES COURT OF APPEALS

For the Fifth Circuit

No. 98-40352

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

VERSUS

JAMES TERRELL DURHAM,

Defendant-Appellant.

Appeal from the United States District Court

for the Eastern District of Texas

(1:97-CR-74-1)

March 1, 1999

Before DAVIS, DUHÉ, and PARKER, Circuit Judges.

PER CURIAM:1

James Terrell Durham appeals his jury conviction for

possession with intent to distribute crack cocaine and conspiracy

to distribute and possess with intent to distribute crack cocaine.

He argues that the district court violated his rights under the

Confrontation Clause by admitting hearsay statements of a

confidential informant and abused its discretion by denying his

motion to compel the Government to disclose the confidential
2

informant’s identity and by admitting evidence of Durham’s prior

felony drug conviction.

The district court did not violate the Confrontation Clause by

admitting testimony regarding the confidential informant’s

statements. The evidence that was offered to show only why law

enforcement officials took certain actions was not hearsay. See

United States v. Evans, 950 F.2d 187, 191 (5th Cir. 1991).

Although the informant’s description of Durham was hearsay, the

district court did not abuse its discretion by admitting that

evidence because Durham opened the door to the question on crossexamination and, if admitted erroneously, the evidence did not have

a substantial impact on the verdict. See id.; United States v.

Walker, 613 F.2d 1349, 1353 (5th Cir. 1980).

The district court did not abuse its discretion by denying

Durham’s request for the disclosure of the informant’s identity.

The informant’s testimony would not have helped Durham’s defense

significantly, and Durham does not dispute the Government’s

interest in nondisclosure. See United States v. Sanchez, 988 F.2d

1384, 1391 (5th Cir. 1993).

The district court did not abuse its discretion by admitting

evidence of Durham’s prior state felony conviction for delivery of

cocaine. The district court determined that the evidence was

material to an issue other than Durham’s character and that its

probative value outweighed its potential prejudice. See United

States v. Beechum, 582 F.2d 898 (5th Cir. 1978) (en banc).

AFFIRMED.
EXHIBIT 32.2

CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Lincare Holdings Inc. (the Company) for the quarter ended June 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Paul G. Gabos, Chief Financial Officer of the Company, certify to the best of my knowledge and belief, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1) | the Report fully complies with the requirements of   Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and                             
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------
| | (2) | information contained in the Report fairly presents,   in all material respects, the financial condition and results of operations   of the Company.

|               | By: | /s/ PAUL G. GABOS        
|-------------- | --- | -------------------------
|               |     |                          
|               |     | Paul G.   Gabos          
|               |     | Chief   Financial Officer
|August 9, 2004 |     |
**EXHIBIT 15**

October 29, 2008 

Bank of America, N.A. as Trustee 

  for the Cross Timbers Royalty Trust: 

Re: Registration Statements No. 33-55784 and No. 333-91460 on Form S-8 

With respect to the subject registration statements, we acknowledge our awareness of the use therein of our report dated October 29, 2008 related to our review ofinterim financial information. 

Pursuant to Rule 436 under the Securities Act of 1933 (the Act), such report is not considered part of a registrationstatement prepared or certified by an independent registered public accounting firm, or a report prepared or certified by an independent registered public accounting firm within the meaning of Sections 7 and 11 of the Act. 

KPMG LLP 

Fort Worth, Texas
EXHIBIT 32.2

STATEMENT OF CHIEF FINANCIAL OFFICER
OF PREMIERE GLOBAL SERVICES, INC.
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
§ 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Premiere Global Services, Inc. (the Company) on Form 10-Q for the quarter ended June 30, 2009 as filed with the Securities and Exchange Commission on the date
hereof (the Report), the undersigned David E. Trine, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1) | The Report fully complies with the requirements of Section
      13(a) or 15(d) of the Securities Exchange Act of 1934; and                                     
| | --- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) | The information contained in the Report fairly presents, in
      all material respects, the financial condition and results of operations
      of the Company.
|

|               |                               
|-------------- | ------------------------------
|August 7, 2009 | /s/ David E. Trine            
|               | David E. Trine                
|               | Chief Financial Officer       
|               | Premiere Global Services, Inc.

---
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 98-6492

JOHN DINO MARTIN, Petitioner - Appellant, versus STATE OF WEST VIRGINIA; ATTORNEY GENERAL OF THE STATE OF WEST VIRGINIA; WEST VIRGINIA DEPARTMENT OF CORRECTIONS; THE UNITED STATES ATTORNEY GENERAL; JOHN DOE, 1-5, Respondents - Appellees. Appeal from the United States District Court for the Northern District of West Virginia, at Wheeling. Frederick P. Stamp, Jr., Chief District Judge. (CA-96-159-5) Submitted: June 18, 1998 Decided: July 9, 1998 Before MURNAGHAN and WILKINS, Circuit Judges, and PHILLIPS, Senior Circuit Judge. Dismissed by unpublished per curiam opinion. John Dino Martin, Appellant Pro Se. Darrell V. McGraw, Jr., Dawn Ellen Warfield, OFFICE OF THE ATTORNEY GENERAL OF WEST VIRGINIA, Charleston, West Virginia; Patrick Michael Flatley, Assistant United States Attorney, Wheeling, West Virginia, for Appellees. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).2 PER CURIAM: Appellant seeks to appeal the district court's order denying relief on his petition filed under 28 U.S.C.A. § 2254 (West 1994 & Supp. 1998). We have reviewed the record and the district court's opinion accepting the recommendation of the magistrate judge and find no reversible error. Accordingly, we deny Appellant’s motion for a certificate of appealability and dismiss the appeal on the reasoning of the district court. Martin v. West Virginia , No. CA96-159-5 (N.D.W. Va. Mar. 27, 1998). We dispense with oral argument because the facts and legal contentions are adequately presented inthe materials before the court and argument would not aid the decisional process.

DISMISSED
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          JAN-30-1999
<PERIOD-START>                             FEB-01-1998
<PERIOD-END>                               MAY-02-1998
<CASH>                                           5,745
<SECURITIES>                                         0
<RECEIVABLES>                                    4,882
<ALLOWANCES>                                         0
<INVENTORY>                                     43,880
<CURRENT-ASSETS>                                56,577
<PP&E>                                         170,912
<DEPRECIATION>                                  67,111
<TOTAL-ASSETS>                                 167,553
<CURRENT-LIABILITIES>                           43,091
<BONDS>                                         27,129
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        78,735
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                   167,553
<SALES>                                         93,690
<TOTAL-REVENUES>                                93,690
<CGS>                                           70,278
<TOTAL-COSTS>                                   70,278
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 911
<INCOME-PRETAX>                                    294
<INCOME-TAX>                                       238
<INCOME-CONTINUING>                                 56
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                        56
<EPS-PRIMARY>                                     0.01
<EPS-DILUTED>                                     0.01
        

</TABLE>
<PAGE>   1

                                   EXHIBIT 11

             STATEMENT REGARDING COMPUTATION OF EARNINGS PER SHARE

                           Three Months
                                Ended
                             March 31, 1997
                             ______________

Net Income                     $647,844
                               ========
Weighted average
shares outstanding            1,256,928

Common stock
equivalents due to dilutive
effect of stock options          66,765
                              ---------
Total weighted average
common shares
and equivalents
outstanding                   1,323,693
                             ==========
Primary earnings
per share                          $.49
                                   ====

Total weighted average
common shares and
equivalents outstanding
for primary computation       1,323,693

Additional dilutive
shares using the end of
period market value versus
the average market value
when applying the treasury
stock method                      3,500*
                              ---------
Total weighted average
common shares and
equivalents outstanding for
fully diluted
computation                    1,327,193
                              ==========

Fully diluted
earnings per share                  $.49
                                    ====

*Note:   If the average share price is greater than the ending price, use 
         average price for both primary and fully diluted calculation.
##### 



(i)
    
    The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and(ii)
    
    The information contained in the Report fairly presents, in
all material respects, the financial condition and results of operation of the
Partnership.
  By
    /s/ Dennis J. TietzDennis J. Tietz,President and Director of Cronos Capital Corp.,
General Partner of the Partnership/s/ Frank P. VaughanFrank P. Vaughan,Chief Financial Officer of Cronos Capital Corp,.
General Partner of the Partnership  
 *
    
    This certification, required by Section 906 of the Sarbanes-Oxley Act of 2002, other than as
required by Section 906, shall not be deemed to be filed with the Commission or subject to
the rules and regulations promulgated by the Commission under the Securities Exchange Act of
1934, as amended, or to the liabilities of Section 18 of said Act.
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

ODYSSEY
MARINE EXPLORATION, INC.

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

I hereby certify that, to the best of my knowledge, the annual report on Form 10-K of Odyssey
Marine Exploration, Inc. for the period ending December 31, 2009, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ----------------------------------------------------------------------------------------------------



| | (2) | the information contained in the Report fairly presents, in all material aspects, the financial condition and results of operations of Odyssey Marine Exploration, Inc.
| | --- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------



|                                                 
|-------------------------------------------------
|/s/    Gregory P.
Stemm                          
|Gregory P. Stemm                                 
|Chairman of the Board and Chief Executive Officer

March 9, 2010

A signed
original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Odyssey Marine Exploration, Inc. and will be retained by Odyssey Marine Exploration, Inc. and furnished to the Securities and
Exchange Commission upon request.



56
Exhibit 32.1


CERTIFICATION OF CHIEF EXECUTIVE OFFICER


Pursuant to 18 U.S.C. § 1350, As Adopted Pursuant to


§ 906 of the Sarbanes-Oxley Act of 2002





In connection with the filing with the Securities and Exchange Commission of the Annual Report of Lakeland Industries, Inc. (the “Company”) on Form 10-K for the year ended January 31, 2011 (the “Report”), I, Christopher J. Ryan, Chief Executive Officer, President, Secretary and General Counsel of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:





(1)      The Report fully complies with the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934; and





(2)      The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.





/s/ Christopher J. RyanChristopher J. RyanChief Executive Officer, President and Secretary





April 7, 2011
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Center for Advancing Translational Sciences Special Emphasis Panel; National Center for Advancing Translational Sciences Special Emphasis Panel.                    

*Date:*                         February 17, 2022.                    

*Time:*                         11:00 a.m. to 1:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Suite 1037, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Alumit Ishai, Ph.D., Scientific Review Officer, Office of Grants Management and Scientific Review, National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Suite 1037, Bethesda, MD 20892, 301-827-5819,                         *alumit.ishai@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: January 10, 2022.

David W. Freeman, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-00675 Filed 1-13-22; 8:45 am]

BILLING CODE 4140-01-P